search
Back to results

Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder

Primary Purpose

Autism Spectrum Disorder, Autism

Status
Available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
Fecal Microbiota Transplant; Vancomycin
Sponsored by
ProgenaBiome
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Autism Spectrum Disorder focused on measuring Fecal Transplant

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All Sexes

Inclusion Criteria:

  1. Diagnosis of Autism Spectrum Disorder
  2. Parent or Legally Authorized Representative willing and able to provide informed consent
  3. A reliable caregiver who can report side effects and communicate effectively with the research team
  4. Stable medications in the two months prior to enrollment
  5. Currently receiving interventions in the community/school for ASD
  6. If female and of childbearing potential, must be willing to utilize at least one highly effective method of birth control for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized)
  7. If male, and partner is of childbearing potential, must be willing to utilize at least one highly effective method of birth control for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be exempt (surgically sterilized)

Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or intend to become pregnant during the study period.
  2. Subjects whose caregivers are unable/unwilling to cooperate with the protocol requirements.
  3. Subject will be excluded who are suffering with Rett syndrome and Childhood Disintegrative Disorder.
  4. Other serious co-morbid medical disorders affecting brain function and behaviour, including uncontrolled seizures.
  5. Subjects unable to refrain from taking non-study antibiotics for the period of the study.
  6. Subjects diagnosed with cancer, except small localized basal cell carcinoma.
  7. Subjects known to abuse alcohol or drugs.
  8. Subjects who have undergone gastric bypass or total colectomy, or who are scheduled for these procedures.
  9. Infection with HIV.
  10. Infection with Hepatitis B or C.
  11. Allergy to benzodiazepine.
  12. Inability to stop loperamide, diphenoxylate/atropine, or cholestyramine before the study
  13. Unable to stop opiate treatment unless on a stable dose including PRN dosing, and no dose increase planned for the duration of the study
  14. Known positive stool cultures for enteropathogens including, but not limited to Shigella, Salmonella, and Campylobacter within 30 days before enrollment.
  15. Known stool studies positive for ova and/or parasites in 30 days prior to enrollment.
  16. Planned travel outside United States during study period.
  17. Hypersensitivity to vancomycin
  18. Renal insufficiency
  19. Colitis

Sites / Locations

  • Ventura Clinical Trials

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
April 28, 2021
Last Updated
September 2, 2021
Sponsor
ProgenaBiome
Collaborators
Topelia Therpeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04878718
Brief Title
Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder
Official Title
Vancomycin and Fecal Microbiota Transplant in a Single Patient for the Treatment of Autism Spectrum Disorder
Study Type
Expanded Access

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ProgenaBiome
Collaborators
Topelia Therpeutics

4. Oversight

5. Study Description

Brief Summary
Single patient with ASD will be treated with Vancomycin followed by FMT.
Detailed Description
A single patient with profound ASD will be treated with Vancomycin. This will be followed by fecal microbiota transplant. The patient will be followed for one year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism Spectrum Disorder, Autism
Keywords
Fecal Transplant

7. Study Design

8. Arms, Groups, and Interventions

Intervention Type
Biological
Intervention Name(s)
Fecal Microbiota Transplant; Vancomycin
Other Intervention Name(s)
FMT, vancomycin
Intervention Description
Subject will be treated with vancomycin followed by fecal microbiota transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Eligibility Criteria
Inclusion Criteria: Diagnosis of Autism Spectrum Disorder Parent or Legally Authorized Representative willing and able to provide informed consent A reliable caregiver who can report side effects and communicate effectively with the research team Stable medications in the two months prior to enrollment Currently receiving interventions in the community/school for ASD If female and of childbearing potential, must be willing to utilize at least one highly effective method of birth control for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized) If male, and partner is of childbearing potential, must be willing to utilize at least one highly effective method of birth control for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be exempt (surgically sterilized) Exclusion Criteria: Female subjects who are pregnant, nursing, or intend to become pregnant during the study period. Subjects whose caregivers are unable/unwilling to cooperate with the protocol requirements. Subject will be excluded who are suffering with Rett syndrome and Childhood Disintegrative Disorder. Other serious co-morbid medical disorders affecting brain function and behaviour, including uncontrolled seizures. Subjects unable to refrain from taking non-study antibiotics for the period of the study. Subjects diagnosed with cancer, except small localized basal cell carcinoma. Subjects known to abuse alcohol or drugs. Subjects who have undergone gastric bypass or total colectomy, or who are scheduled for these procedures. Infection with HIV. Infection with Hepatitis B or C. Allergy to benzodiazepine. Inability to stop loperamide, diphenoxylate/atropine, or cholestyramine before the study Unable to stop opiate treatment unless on a stable dose including PRN dosing, and no dose increase planned for the duration of the study Known positive stool cultures for enteropathogens including, but not limited to Shigella, Salmonella, and Campylobacter within 30 days before enrollment. Known stool studies positive for ova and/or parasites in 30 days prior to enrollment. Planned travel outside United States during study period. Hypersensitivity to vancomycin Renal insufficiency Colitis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sabine Hazan, MD
Phone
805-339-0549
Email
drsabinehazan@progenabiome.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jordan E Daniels, MS
Phone
805-339-0549
Email
jordan@progenabiome.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sabine Hazan, MD
Organizational Affiliation
ProgenaBiome
Official's Role
Study Director
Facility Information:
Facility Name
Ventura Clinical Trials
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Individual Site Status
Available
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Hazan, MD
Phone
805-339-0549
Email
drsabinehazan@progenabiome.com
First Name & Middle Initial & Last Name & Degree
Jordan E Daniels, MS
Phone
18053390549
Email
jordan@progenabiome.com

12. IPD Sharing Statement

Learn more about this trial

Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder

We'll reach out to this number within 24 hrs